536,829 Shares in CeriBell, Inc. (NASDAQ:CBLL) Bought by TimesSquare Capital Management LLC

TimesSquare Capital Management LLC bought a new stake in CeriBell, Inc. (NASDAQ:CBLL - Free Report) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 536,829 shares of the company's stock, valued at approximately $10,312,000. TimesSquare Capital Management LLC owned 1.50% of CeriBell at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in CBLL. Legal & General Group Plc bought a new position in CeriBell during the 4th quarter valued at $32,000. Summit Investment Advisors Inc. bought a new position in CeriBell during the 4th quarter valued at $33,000. Tower Research Capital LLC TRC bought a new position in CeriBell during the 4th quarter valued at $37,000. BNP Paribas Financial Markets bought a new position in CeriBell during the 4th quarter valued at $43,000. Finally, PNC Financial Services Group Inc. bought a new position in CeriBell during the 4th quarter valued at $47,000.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on CBLL shares. LADENBURG THALM/SH SH started coverage on CeriBell in a research note on Friday, April 4th. They set a "buy" rating and a $32.00 price target for the company. BTIG Research assumed coverage on CeriBell in a research note on Tuesday, June 24th. They set a "buy" rating and a $30.00 price target for the company. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, CeriBell currently has a consensus rating of "Buy" and a consensus price target of $32.14.

Insiders Place Their Bets

In other news, Director Rebecca B. Robertson sold 11,188 shares of the stock in a transaction on Wednesday, June 18th. The stock was sold at an average price of $17.85, for a total value of $199,705.80. Following the completion of the sale, the director owned 10,042 shares in the company, valued at $179,249.70. This represents a 52.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Xingjuan Chao sold 25,000 shares of the stock in a transaction on Monday, July 7th. The shares were sold at an average price of $17.70, for a total value of $442,500.00. Following the completion of the sale, the chief executive officer owned 776,022 shares of the company's stock, valued at $13,735,589.40. The trade was a 3.12% decrease in their position. The disclosure for this sale can be found here. Insiders sold 132,633 shares of company stock valued at $2,252,081 in the last 90 days. Corporate insiders own 20.10% of the company's stock.

CeriBell Trading Down 1.1%

Shares of CBLL traded down $0.18 during trading hours on Friday, hitting $15.45. 118,103 shares of the company were exchanged, compared to its average volume of 288,679. The company has a debt-to-equity ratio of 0.11, a quick ratio of 16.81 and a current ratio of 17.36. The firm has a fifty day simple moving average of $17.49 and a 200-day simple moving average of $19.40. CeriBell, Inc. has a one year low of $10.01 and a one year high of $32.75.

CeriBell (NASDAQ:CBLL - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.07. The company had revenue of $20.49 million for the quarter, compared to the consensus estimate of $19.30 million. As a group, analysts anticipate that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.

CeriBell Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.